ImClone is a healthcare company in the biotechnology and drugs industry. This corporation deals with the development of life saving, life altering, and life prolonging drugs for people with a variety of cancers. ImClone is in the same biotechnology research fields as the other drugs companies such as Medarex Incorporated, Abgenix Incorporated, Amgen Incorporated, Genentech, Incorporated, OSI Pharmaceuticals Incorporated, CancerVax Corporation, Onyx Pharmaceuticals Incorporated, Ariad Pharmaceuticals Incorporated, Pfizer Incorporated, and Vion Pharmaceuticals Inc. Being in the same sector as these other massive companies, ImClone is just as large but significantly younger. The oncology field of companies has dramatically heightened in the past twenty five years as a direct result of the population increase being directly correlated with the heightened cancer diagnosis. ImClone was and still is the hottest young biotechnology firm in the market (Reuters.com).
ImClone was founded by Sam Waksal in 1982 as an effort to help close acquaintances of his deal with their newly diagnosed infectious diseases. Samuel D. Waksal was born on september 8, 1947 in Paris, France. Samuel and his parents moved from France to the United States of America where he attended Ohio Statue University. He graduated with a premedical degree in 1967. Sam Waksal attended Ohio State University Medical School where in 1974 he graduated with a doctor of philosophy degree in 1974.
Incorporated on April 26, 1984, Mr. Samuel D. Waksal and his ImClone company began developing a portfolio of targeted biological treatments designed to address the medical needs of patients with cancer (Reuters.com). ImClone uses two very distinct systems for treating certain forms of terminal cancers: ...